scispace - formally typeset
Search or ask a question
Institution

Novartis

CompanyBasel, Switzerland
About: Novartis is a company organization based out in Basel, Switzerland. It is known for research contribution in the topics: Alkyl & Population. The organization has 41930 authors who have published 50566 publications receiving 1978996 citations. The organization is also known as: Novartis International AG.
Topics: Alkyl, Population, Alkoxy group, Receptor, Cancer


Papers
More filters
Journal ArticleDOI
20 Aug 1999-Science
TL;DR: Pig organs may offer a solution to the shortage of human donor organs for transplantation, but concerns remain about possible cross-species transmission of porcine endogenous retrovirus (PERV), and persistent microchimerism was observed in 23 patients for up to 8.5 years.
Abstract: Pig organs may offer a solution to the shortage of human donor organs for transplantation, but concerns remain about possible cross-species transmission of porcine endogenous retrovirus (PERV). Samples were collected from 160 patients who had been treated with various living pig tissues up to 12 years earlier. Reverse transcription–polymerase chain reaction (RT-PCR) and protein immunoblot analyses were performed on serum from all 160 patients. No viremia was detected in any patient. Peripheral blood mononuclear cells from 159 of the patients were analyzed by PCR using PERV-specific primers. No PERV infection was detected in any of the patients from whom sufficient DNA was extracted to allow complete PCR analysis (97 percent of the patients). Persistent microchimerism (presence of donor cells in the recipient) was observed in 23 patients for up to 8.5 years.

705 citations

Journal ArticleDOI
TL;DR: Benzo(1,2,3)-thiadiazole-7-carbothioic acid S-methyl ester induces SAR based on all of the physiological and biochemical criteria that define SAR in tobacco.
Abstract: Summary Systemic acquired resistance (SAR) is a pathogen-induced disease resistance response in plants that is characterized by broad spectrum disease control and an associated coordinate expression of a set of SAR genes. Benzo(1,2,3)-thiadiazole-7-carbothioic acid S-methyl ester (BTH) is a novel synthetic chemical capable of inducing disease resistance in a number of dicotyledenous and monocotyledenous plant species. In this report, the response of tobacco plants to BTH treatment is characterized and the fact that it controls disease by activating SAR is demonstrated. BTH does not cause an accumulation of salicylic acid (SA), an intermediate in the SAR signal transduction pathway. As BTH also induces disease resistance and gene expression in transgenic plants expressing the nahG gene, it appears to activate the SAR signal transduction pathway at the site of or downstream of SA accumulation. BTH, SA and TMV induce the PR-1a promoter using similar cis-acting elements and gene expression is blocked by cycloheximide treatment. Thus, BTH induces SAR based on all of the physiological and biochemical criteria that define SAR in tobacco.

704 citations

Journal ArticleDOI
TL;DR: Responses to all hepatitis C virus antigens were significantly more vigorous and more frequently detectable in patients who normalized transaminase levels than in those who did not, suggesting that the vigor of the T cell response during the early stages of infection may be a critical determinant of disease resolution and control.
Abstract: The anti-viral T cell response is believed to play a central role in the pathogenesis of hepatitis C virus infection. Since chronic evolution occurs in > 50% of HCV infections, the sequential analysis of the T cell response from the early clinical stages of disease may contribute to define the features of the T cell response associated with recovery or chronic viral persistence. For this purpose, 21 subjects with acute hepatitis C virus infection were sequentially followed for an average time of 44 wk. Twelve patients normalized transaminase values that remained normal throughout the follow-up period; all but two cleared hepatitis C virus-RNA from serum. The remaining nine patients showed persistent viremia and elevated transaminases. Analysis of the peripheral blood T cell proliferative response to core, E1, E2, NS3, NS4, and NS5 recombinant antigens and synthetic peptides showed that responses to all hepatitis C virus antigens, except E1, were significantly more vigorous and more frequently detectable in patients who normalized transaminase levels than in those who did not. By sequential evaluation of the T cell response, a difference between the two groups of patients was already detectable at the very early stages of acute infection and then maintained throughout the follow-up period. The results suggest that the vigor of the T cell response during the early stages of infection may be a critical determinant of disease resolution and control of infection.

704 citations

Journal ArticleDOI
TL;DR: New insights into the effects of targeted therapies, along with conventional chemotherapy and radiation therapy, on the induction of antitumour immunity will help to advance the design of combination strategies that increase the rate of complete and durable clinical response in patients.
Abstract: Over the past 25 years, research in cancer therapeutics has largely focused on two distinct lines of enquiry. In one approach, efforts to understand the underlying cell-autonomous, genetic drivers of tumorigenesis have led to the development of clinically important targeted agents that result in profound, but often not durable, tumour responses in genetically defined patient populations. In the second parallel approach, exploration of the mechanisms of protective tumour immunity has provided several therapeutic strategies - most notably the 'immune checkpoint' antibodies that reverse the negative regulators of T cell function - that accomplish durable clinical responses in subsets of patients with various tumour types. The integration of these potentially complementary research fields provides new opportunities to improve cancer treatments. Targeted and immune-based therapies have already transformed the standard-of-care for several malignancies. However, additional insights into the effects of targeted therapies, along with conventional chemotherapy and radiation therapy, on the induction of antitumour immunity will help to advance the design of combination strategies that increase the rate of complete and durable clinical response in patients.

703 citations

Journal ArticleDOI
Jun Kawai, Akira Shinagawa, K. Shibata, Masayasu Yoshino, Masayoshi Itoh, Y. Ishii, Takahiro Arakawa, A. Hara, Yoshifumi Fukunishi, Hideaki Konno, Jun Adachi, S. Fukuda, Katsunori Aizawa, Masaki Izawa, Kenichiro Nishi, H. Kiyosawa, S. Kondo, Itaru Yamanaka, Takashi Saito, Yasushi Okazaki, Takashi Gojobori1, Hidemasa Bono, Takeya Kasukawa2, Rintaro Saito, Koji Kadota, Hideo Matsuda3, Michael Ashburner, Serge Batalov4, Thomas L. Casavant5, W. Fleischmann, Terry Gaasterland6, Carmela Gissi7, Benjamin L. King, Hiromi Kochiwa8, P. Kuehl9, Simon L. Lewis10, Y. Matsuo, Itoshi Nikaido11, Graziano Pesole7, John Quackenbush12, Lynn M. Schriml13, F. Staubli, R. Suzuki8, Masaru Tomita8, Lukas Wagner13, Takanori Washio8, K. Sakai, Toshihisa Okido, Masaaki Furuno, H. Aono, Richard M. Baldarelli, Gregory S. Barsh14, Judith A. Blake, Dario Boffelli15, N. Bojunga, Piero Carninci, M. F. De Bonaldo5, Michael J. Brownstein13, Carol J. Bult, Christopher D.M. Fletcher4, Masaki Fujita16, Manuela Gariboldi, Stefano Gustincich17, David E. Hill, Marion A. Hofmann, David A. Hume18, Mamoru Kamiya, Norman H. Lee12, Paul A. Lyons19, Luigi Marchionni20, Jun Mashima1, J. Mazzarelli21, Peter Mombaerts6, P. Nordone22, Brian Z. Ring14, M. Ringwald, Ivan Rodriguez6, Naoaki Sakamoto, H. Sasaki23, K. Sato24, Christian Schönbach, Tsukasa Seya, Y. Shibata, Kai-Florian Storch, Harukazu Suzuki, Kazuhito Toyo-oka25, Kuan Hong Wang26, Charles J. Weitz17, Charles A. Whittaker26, L. Wilming27, Anthony Wynshaw-Boris25, K. Yoshida, Y. Hasegawa2, Hideya Kawaji2, Hideya Kawaji3, S. Kohtsuki2, Yoshihide Hayashizaki24 
08 Feb 2001-Nature
TL;DR: The first RIKEN clone collection is described, which is one of the largest described for any organism and analysis of these cDNAs extends known gene families and identifies new ones.
Abstract: The RIKEN Mouse Gene Encyclopaedia Project, a systematic approach to determining the full coding potential of the mouse genome, involves collection and sequencing of full-length complementary DNAs and physical mapping of the corresponding genes to the mouse genome. We organized an international functional annotation meeting (FANTOM) to annotate the first 21,076 cDNAs to be analysed in this project. Here we describe the first RIKEN clone collection, which is one of the largest described for any organism. Analysis of these cDNAs extends known gene families and identifies new ones.

700 citations


Authors

Showing all 41972 results

NameH-indexPapersCitations
Irving L. Weissman2011141172504
Peter J. Barnes1941530166618
Paul G. Richardson1831533155912
Kenneth C. Anderson1781138126072
Jie Zhang1784857221720
Lei Jiang1702244135205
Marc A. Pfeffer166765133043
Jorge E. Cortes1632784124154
Ian A. Wilson15897198221
Peter G. Schultz15689389716
Bruce D. Walker15577986020
Timothy P. Hughes14583191357
Kurt Wüthrich143739103253
Leonard Guarente14335280169
Christopher D.M. Fletcher13867482484
Network Information
Related Institutions (5)
Pfizer
37.4K papers, 1.6M citations

97% related

Merck & Co.
48K papers, 1.9M citations

97% related

GlaxoSmithKline
21.1K papers, 1.1M citations

97% related

Hoffmann-La Roche
43K papers, 1.6M citations

96% related

Genentech
17.1K papers, 1.4M citations

95% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202318
202285
20211,321
20201,377
20191,376
20181,456